Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1
- PMID: 7584058
Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1
Abstract
T-cell lines (Jurkat and Molt-4) were transduced with retroviral vectors containing a hairpin ribozyme that targets a conserved sequence in the 5' transcribed leader sequence of human immunodeficiency virus (HIV) type 1. Stable cell lines were generated which constitutively and persistently expressed the ribozyme gene driven by either the Moloney retroviral long terminal repeat (LTR) or an internal human tRNA(val) promoter. There was no apparent deleterious effect of long-term ribozyme expression on cell proliferation or viability. Cells expressing ribozyme were resistant to challenge from diverse strains of HIV, including an uncloned clinical isolate. No reverse transcriptase activity or virus infectivity was detectable in the culture supernatants of Jurkat cells expressing the ribozyme driven by the tRNA(val) promoter up to 35 days after challenge with HIV-1/HXB2. Expression of the ribozyme also significantly decreased (by approximately 50- to 100-fold) the efficiency of incoming virus to synthesize viral DNA. These and previously reported results indicate that transfer and expression of the ribozyme gene interfere with both early and late events in the HIV replication cycle and confer long-term resistance to HIV-1 infection.
Similar articles
-
Intracellular immunization against SIVmac utilizing a hairpin ribozyme.Virology. 1996 Feb 1;216(1):241-4. doi: 10.1006/viro.1996.0055. Virology. 1996. PMID: 8614996
-
Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.Virology. 1994 Nov 15;205(1):121-6. doi: 10.1006/viro.1994.1626. Virology. 1994. PMID: 7975207
-
Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.Virology. 1996 Jun 15;220(2):377-89. doi: 10.1006/viro.1996.0326. Virology. 1996. PMID: 8661389
-
[Inhibition of HIV replication by ribozyme strategy].Tanpakushitsu Kakusan Koso. 1995 Jul;40(10):1421-9. Tanpakushitsu Kakusan Koso. 1995. PMID: 7568943 Review. Japanese. No abstract available.
-
Ribozyme therapy for HIV infection.Adv Drug Deliv Rev. 2000 Oct 31;44(1):71-8. doi: 10.1016/s0169-409x(00)00085-5. Adv Drug Deliv Rev. 2000. PMID: 11035199 Review.
Cited by
-
U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus.Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7219-24. doi: 10.1073/pnas.93.14.7219. Proc Natl Acad Sci U S A. 1996. PMID: 8692972 Free PMC article.
-
A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.J Virol. 1995 Nov;69(11):6618-26. doi: 10.1128/JVI.69.11.6618-6626.1995. J Virol. 1995. PMID: 7474070 Free PMC article.
-
Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3406-11. doi: 10.1073/pnas.052651199. Proc Natl Acad Sci U S A. 2002. PMID: 11904403 Free PMC article.
-
Ribozymes. Their functions and strategies for their use.Mol Biotechnol. 1997 Apr;7(2):125-37. doi: 10.1007/BF02761748. Mol Biotechnol. 1997. PMID: 9219227 Review.
-
Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs.Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7272-6. doi: 10.1073/pnas.92.16.7272. Proc Natl Acad Sci U S A. 1995. PMID: 7638180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical